造血细胞移植供者来源的记忆样NK细胞在白血病患者体内输注后功能性持续存在
该临床试验在15例复发/难治性急性髓系白血病患者中,将同供者记忆样NK细胞联合3周N-803加入减低强度预处理HLA单倍体造血细胞移植。供者记忆样NK细胞耐受良好,87%患者在第+28天达到复合完全缓解,并对应清除TP53变异等高危突变;NK细胞在移植后2个月内为主要血液淋巴细胞,扩增达1104倍,表型与转录分析显示其不同于常规NK细胞且持续超过2个月,体外功能增强。
要点
- 同供者记忆样NK细胞联合3周N-803支持减低强度预处理HLA单倍体造血细胞移植耐受良好。
- 15例复发/难治性AML患者中87%在第+28天达到复合完全缓解,对应清除包括TP53变异在内的高危突变。
- 供者记忆样NK细胞在移植后2个月内为主要血液淋巴细胞,扩增达1104倍,并持续超过2个月。
核心结论
- 同供者记忆样NK细胞联合3周N-803支持可安全增强减低强度预处理HLA单倍体造血细胞移植用于急性髓系白血病。
研究设计与样本
- 临床试验(NCT02782546)在15例复发/难治性急性髓系白血病患者中,于减低强度预处理HLA单倍体造血细胞移植第+7天输注同供者记忆样NK细胞并给予3周N-803。
主要发现
- 15例患者中供者记忆样NK细胞耐受良好,87%患者在第+28天达到复合完全缓解,并对应清除包括TP53变异在内的高危突变。
- 移植后2个月内NK细胞为主要血液淋巴细胞,扩增达1104倍(历时1至2周)。
- 表型与转录分析显示供者记忆样NK细胞不同于常规NK细胞,且持续超过2个月。
- 记忆样NK细胞表达CD16、CD57及高颗粒酶B和穿孔素,并具有独特转录因子谱。
- 患者体内分化的记忆样NK细胞体外功能较患者和健康供者的常规NK细胞增强。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Natural killer (NK) cells are innate lymphoid cells that eliminate cancer cells, produce cytokines, and are being investigated as a nascent cellular immunotherapy. Impaired NK cell function, expansion, and persistence remain key challenges for optimal clinical translation. One promising strategy to overcome these challenges is cytokine-induced memory-like (ML) differentiation, whereby NK cells acquire enhanced antitumor function after stimulation with interleukin-12 (IL-12), IL-15, and IL-18. Here, reduced-intensity conditioning (RIC) for HLA-haploidentical hematopoietic cell transplantation (HCT) was augmented with same-donor ML NK cells on day +7 and 3 weeks of N-803 (IL-15 superagonist) to treat patients with relapsed/refractory acute myeloid leukemia (AML) in a clinical trial (NCT02782546). In 15 patients, donor ML NK cells were well tolerated, and 87% of patients achieved a composite complete response at day +28, which corresponded with clearing high-risk mutations, including TP53 variants. NK cells were the major blood lymphocytes for 2 months after HCT with 1104-fold expansion (over 1 to 2 weeks). Phenotypic and transcriptional analyses identified donor ML NK cells as distinct from conventional NK cells and showed that ML NK cells persisted for over 2 months. ML NK cells expressed CD16, CD57, and high granzyme B and perforin, along with a unique transcription factor profile. ML NK cells differentiated in patients had enhanced ex vivo function compared to conventional NK cells from both patients and healthy donors. Overall, same-donor ML NK cell therapy with 3 weeks of N-803 support safely augmented RIC haplo-HCT for AML.
引用
- Berrien-Elliott MM, Foltz JA, Russler-Germain DA, et al. Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. Sci Transl Med. 2022. PMID: 35196021. doi:10.1126/scitranslmed.abm1375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。